This journal is
indexed in Scopus

Year 2022 Vol. 30 No 2


DOI:   |  



Medical Centre Antes Med 1,
N.N.Alexandrov National Cancer Centre of Belarus 2,
Republican Clinical Medical Center" of the Administration of the President of the Republic of Belarus 3,
Belarusian Medical Academy of Postgraduate Education 4, Minsk,
The Republic of Belarus

Breast augmentation with implants is one of the most popular plastic surgery procedures. Experience and clinical observations have revealed an association between breast augmentation with implants and a special type of lymphoma that occurs around them breast-implant-associated anaplastic large cell lymphoma (BIA-ALCL), which resulted in changing of the selection criteria for implant and restrictive measures in several countries. The authors present the first case of breast-implant-associated anaplastic large-cell lymphoma in Belarus. Breast implant augmentation-mastopexy for cosmetic reasons had been performed 9 years before the diagnosis of lymphoma made. The implants of the 3rd group of texture according to ISO classification were used. The disease manifested with seroma of the right breast. Prior the surgery (capsulectomy and reaugmentation with implants) due to the patients refusal to undergo the surgical treatment, several aspirations to obtain fluid for analysis to diagnose were performed. Final diagnosis was BIA-ALCL, stage 1a. The patient has been followed up for 1,5 years and there was no recurrence. This study provides a literature review of recent scientific publications concerning this issue and testifies an increase in the number of cases, the majority of them manifest themselves only as seroma, and total capsulectomy is a sufficient and final treatment. Today the presence of breast implants without definite symptoms is not an indication for implant removal or replacement. The authors consider it rational to create a national registry of implants with the aim of an analytical approach to possible associations with pathological conditions.

Keywords: implant-associated lymphoma, breast augmentation implants, anaplastic large cell lymphoma, late seroma, breast implants, textured implants, capsulectomy
p. 228-235 of the original issue
  1. ISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2018 [Electronic resource]. ISAPS Official Data, 2018]. Available from:
  2. Keech JA Jr, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997 Aug;100(2):554-5. doi: 10.1097/00006534-199708000-00065
  3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569
  4. National Comprehensive Cancer Network Guidelines in Oncology. T-Cell Lymphomas [Electronic resource]. National Comprehensive Cancer Network
  5. Profile: investigating BIA-ALCL and Breast Implants. [Electronic resource]. The Plastic Surgery Foundation.
  6. FDA Updates Analysis of Medical Device Reports of Breast Implant Illness and Breast Implant-Associated Lymphoma [Electronic resource]. Food and Drug Administration.
  7. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, Parkash V, Ning J, Sohani AR, Ferry JA, Mehta-Shah N, Dogan A, Liu H, Thormann N, Di Napoli A, Lade S, Piccolini J, Reyes R, Williams T, McCarthy CM, Hanson SE, Nastoupil LJ, Gaur R, Oki Y, Young KH, Miranda RN. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. J Clin Oncol. 2016 Jan 10;34(2):160-8. doi: 10.1200/JCO.2015.63.3412
  8. Cordeiro PG, Ghione P, Ni A, Hu Q, Ganesan N, Galasso N, Dogan A, Horwitz SM. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg. 2020 May;73(5):841-846. doi: 10.1016/j.bjps.2019.11.064
  9. BIA-ALCL Physician Resources [Electronic resource]. American Society of Plastic Surgeons.
  10. Rastogi P, Riordan E, Moon D, Deva AK. Theories of Etiopathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):23S-29S. doi: 10.1097/PRS.0000000000005566
  11. SCHEER (Scientific Committee on Health, Environmental and Emerging Risks), Scientific Opinion on the safety of breast implants in relation to anaplastic large cell lymphoma, 26 March 2021.
  12. Hojo N, Yakushijin Y, Narumi H, Minamoto Y, Sakai I, Takada K, Hato T, Yasukawa M, Fujita S. Non-Hodgkins lymphoma developing in a pacemaker pocket. Int J Hematol. 2003 May;77(4):387-90. doi: 10.1007/BF02982649
  13. Fleming D, Stone J, Tansley P. Update: Spontaneous Regression and Resolution of Breast Implant-Associated Anaplastic Large Cell Lymphoma-Implications for Research, Diagnosis and Clinical Management-Our Reflections and Current Thoughts Two Years On. Aesthetic Plast Surg. 2020 Aug;44(4):1116-19. doi: 10.1007/s00266-020-01771-6
  14. de Boer M, van Leeuwen FE, Hauptmann M, Overbeek LIH, de Boer JP, Hijmering NJ, Sernee A, Klazen CAH, Lobbes MBI, van der Hulst RRWJ, Rakhorst HA, de Jong D. Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. JAMA Oncol. 2018 Mar 1;4(3):335-41. doi: 10.1001/jamaoncol.2017.4510
  15. Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthet Surg J. 2019 Jan 31;39(Suppl_1):S3-S13. doi: 10.1093/asj/sjy331
  16. Mehta-Shah N, Clemens MW, Horwitz SM. How I treat breast implant-associated anaplastic large cell lymphoma. Blood. 2018 Nov 1;132(18):1889-98. doi: 10.1182/blood-2018-03-785972
  17. FDA takes action to protect patients from risk of certain textured breast implants; requests Allergan voluntarily recall certain breast implants and tissue expanders from market [Electronic resource]. Food and Drug Administration.
Address for correspondence:
220037, Republic of Belarus,
Minsk, Kozlov Lane, 25-6,
Medical Centre Antes Med
tel. +375 29 611-49-91,
Batiukov Dmitry V.
Information about the authors:
Batiukov Dmitry V., PhD, Head of the Surgical Department, Medical Centre Antes Med, Minsk, Republic of Belarus.
Erokhina Oxana A., PhD, Head of the Cytological Laboratory, N.N.Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus.
Ydzina Olha A., PhD, Associate Professor, Pathologist, Republican Clinical Medical Center of the Administration of the President of the Republic of Belarus, Minsk, Republic of Belarus.
Dubrouski Aliaxandr Ch., PhD, Head of the Pathological Unit, N.N.Alexandrov National Cancer Centre of Belarus, Minsk, Republic of Belarus.
Podgaiski Vladimir N., MD, Professor, Head of the Plastic Surgery and Combustiology Department, Belarusian Medical Academy of Postgraduate Education, Minsk, Republic of Belarus.
Contacts | ©Vitebsk State Medical University, 2007